RecruitingNCT06830590
Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
Sponsor
Liaquat University of Medical & Health Sciences
Enrollment
300 participants
Start Date
Feb 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC
Eligibility
Sex: FEMALE
Plain Language Summary
Simplified for easier understanding
This study is examining the biological characteristics of early-stage breast cancer in Pakistani women. Researchers will analyze tumor samples to understand how breast cancer behaves differently in this population, which could improve how it is diagnosed and treated locally.
**You may be eligible if...**
- You are a woman with a confirmed breast cancer diagnosis
- Your cancer has not been treated with chemotherapy or other systemic therapy before surgery
- A good quality tumor tissue sample is available for laboratory analysis
**You may NOT be eligible if...**
- You have already received chemotherapy or radiation therapy before surgery (called neoadjuvant treatment)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREMolecular characterisation
All patients treated by surgery were included without any neoadjuvant therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06830590
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations